Tag Archives | PViMS

Philippines Uses PViMS App to Roll out Groundbreaking Tuberculosis Drug

The Philippines has one of the highest TB burdens in the world—and 2.6% of its more than 286,000 new cases in 2015 were of multi-drug-resistant TB (MDR-TB). This threatens the progress the country has made in addressing the deadly disease over the past few decades and its goal to make the country TB-free by 2030. […]

Read full story · Comments { 0 }

Pharmacovigilance Monitoring System (PViMS) User Guide

The user guide primarily serves as a reference in reporting an adverse event (AE) through PViMS. It also serves to guide reporters and investigators in completing a correct and accurate AE report. This guide outlines the key data needed, starting from the initial alert to the completion of an AE report in PViMS.

Read full story · Comments are closed

SIAPS Launches Innovative Digital Health Tool in Georgia to Monitor Adverse Drug Reactions

In April 2015, the US Agency for International Development (USAID) and Janssen Therapeutics officially launched the bedaquiline donation initiative. As part of this initiative, Janssen committed to providing bedaquiline at no cost to 30,000 patients with multidrug-resistant tuberculosis (MDR-TB) over a four-year period. Bedaquiline is the first anti-TB medicine to be approved by the U.S. Food […]

Read full story · Comments { 0 }

Bedaquiline Treatment Reaches 200 Patients in Georgia

Georgia is one of the first countries to benefit from the USAID‑Janssen Therapeutics bedaquiline (BDQ) donation program. Along with delamanid, BDQ is one of only two new TB medicines released to the market in over 40 years. These medicines are being used for the treatment of MDR-TB patients, as well as TB patients who have […]

Read full story · Comments { 0 }

SIAPS launches new PViMS tool for improved pharmacovigilance

This week, at the 46th Union World Conference on Lung Health, the USAID-funded SIAPS Program is launching a new tool to improve pharmacovigilance in low- and middle-income countries. Although all medicines undergo rigorous clinical testing prior to being made publicly available, continuing to monitor the safety and effectiveness of medicines in real world settings, also referred to […]

Read full story · Comments { 1 }